Better Mood stack (nasal)
PE-22-28 AM + Selank PM — spray (nasal), vials or cartridges
3.114.000 ₫
Vial-by-vial breakdown
A streamlined two-peptide nootropic protocol focused on mood and emotional regulation. PE-22-28 in the morning for fast-acting mood support and synaptic plasticity (TREK-1 inhibition, BDNF upregulation), Selank in the evening for calm focus and anxiolytic effect without sedation. The pairing targets the two most common failure modes in mood-driven dysregulation — daytime flatness or low drive, and evening anxiety or rumination — through complementary, non-monoaminergic mechanisms that avoid the side-effect profile of SSRIs. Available in three delivery formats — nasal spray is the most popular: (a) Two nasal sprays — easy daily use (b) Two SubQ vials — ~100% more bioavailability (c) Two pre-loaded cartridges — convenient pen delivery Tier sizing is per peptide per bottle.
Dosage
PE-22-28 spray (AM): 1-2 sprays per nostril Selank spray (PM): 1-2 sprays per nostril (~200µg each)
Duration of effect
Effects felt for 6-24 hours per dose (plasma ~5-15 min · downstream TREK-1 / BDNF effects days)
See full half-life table →Key Features
- Two nasal sprays — no injection
- AM mood/focus + PM calm split
- Cold-chain delivery
- Streamlined 2-peptide protocol
Includes key details, half-life data, usage notes and research sources.
Usage Instructions
Can be administered nasally or subcutaneously. Daily or cyclical dosing. Best taken in the morning for optimal cognitive effects.
Research Highlights
- Backed by scientific research
- Manufactured to pharmaceutical standards
- Used in clinical research settings
- Established safety profile
Safety Information
- •Consult your healthcare provider before use
- •Not intended for pregnant or nursing women
- •Store properly according to instructions
- •Report any adverse effects to your healthcare provider
Source: Frontiers in Pharmacology, 2017
Clinical Research
PE 22-28, a shorter analog of spadin, retains the antidepressant properties of spadin by blocking TREK-1 channels, with effects observed after only 4 days of treatment in animal models — a marked acceleration compared with classical antidepressants.
Read full studyAdditional Research
Source: Zozulia et al., Korsakov J Neurology & Psychiatry (2008)
In a 62-patient human trial of generalized anxiety disorder, Selank produced anxiolytic effects comparable to medazepam without sedation, dependence, or cognitive impairment — pairing well with PE-22-28's fast-onset mood support.
Read full study